Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P360: Inflammatory microheterogeneity in ulcerative colitis: implications for microscopic assessment of disease activity

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Harpaz1,2, S. Ballentine1, B. E. Sands2, J-F. Colombel2, H. M. Ko*1,2

1Icahn School of Medicine at Mount Sinai, Department of Pathology, New York, USA, 2Icahn School of Medicine at Mount Sinai, Department of Medicine, Gastroenterology, New York, USA

P361: Laboratory criteria of infliximab therapy inefficiency in children with IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Potapov*1, T. Radigina2, S. Petrichuk2, D. Gerasimova2, A. Illarionov1,3, A. Anushenko1, T. Erlikh-Fox4

1National Medical Research Center for Children's Health, Gastroenterology and Hepatology, Moscow, Russian Federation, 2National Medical Research Center for Children's Health, Laboratory of Experimental Immunology and Virology, Moscow, Russian Federation, 3Sechenov First Moscow State Medical University, Department of Peliatrics and Rheumatology, Moscow, Russian Federation, 4National Medical Research Center for Children's Health, Cytochemical Research Center, Moscow, Russian Federation

P362: Faecal calprotectin is an early predictor of endoscopic response and histological remission after the start of vedolizumab

ECCO '19 Copenhagen

Year: 2019
Authors:

R. W. M. Pauwels*1, A. C. de Vries1, J. C. Goet1, N. S. Erler2, C. J. van der Woude1

1Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2Erasmus MC, Department of Biostatistics, Rotterdam, The Netherlands

P363: The minimal invasive surgery in combination with negative pressure wound therapy for perianal fistulas in Crohn’s colitis lead to the fast introduction of the biological treatment and improve the results

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Banasiewicz*1, J. Paszkowski1, J. Hermann1, J. Cwalinski1, P. Eder2, K. Stawczyk-Eder2, K. Waszak2, A. Dobrowolska2

1University of Medical Sciences, General, Endocrinological Surgery and Gastrointestinal Oncology, Poznań, Poland, 2University of Medical Sciences, Department of Gastroenterology, Poznan, Poland

P364: The value of faecal calprotectin for assessing endoscopic activity and predicting future clinical course in patients with active ulcerative colitis treated with granulomonocytapheresis: a prospective study

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Shimoyama*1, T. Yamamoto1, S. Umegae1, K. Matsumoto1

1Yokkaichi Hazu Medical Centre, IBD Centre, Yokkaichi, Japan

P365: Autologous haematopoietic stem cell transplantation in refractory Crohn’s disease: experience of a Brazilian tertiary centre

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Oba*1,2, F. Steinwurz2, A. Scanavini Neto3, O. Ambrogini4, C. Silva5, S. Nakashima5, M. Santos5, N. Hamerschlak6

1São Paulo University Medical School, Pediatric, São Paulo, Brazil, 2Hospital Israelita Albert Einstein, GI, São Paulo, Brazil, 3Hospital Israelita Albert Einstein, Surgery, São Paulo, Brazil, 4UNIFESP-EPM, GI, SP, Brazil, 5Hospital Israelita Albert Einstein, Research, São Paulo, Brazil, 6Hospital Israelita Albert Einstein, Oncology-hematology, São Paulo, Brazil

P366: A service evaluation of pre-operative nutritional optimisation in patients with Crohn’s disease using exclusive enteral nutrition with or without supplementary parenteral nutrition

ECCO '19 Copenhagen

Year: 2019
Authors:

D. O'Hanlon1, A. Sandall1,2, A. Darakhshan3, A. Williams3, E. Westcott3, K. Patel4, P. Irving4, M. Lomer1,2

1Guy's and St.Thomas' NHS Foundation Trust, Nutrition and Dietetics, London, UK, 2King's College London, Nutritional Sciences Division, London, UK, 3Guy's and St. Thomas' NHS Foundation Trust, Colorectal Surgery, London, UK, 4Guy's and St. Thomas' NHS Foundation Trust, Gastroenterology, London, UK

P367: Nutrition advice for IBD patients as a useful complementary strategy: a single-centre cohort intervention

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Fortuna1, M. Di Ruscio*1, A. Variola1, A. Massella1, A. Geccherle1

1Multispecialistic Centre for Recto-Perineal Diseases (IBD Unit), Department of Gastroenterology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar (Verona), Italy

P368: Vedolizumab in inflammatory bowel disease: a retrospective single-centre study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Larsson*1, M. Henriksen1, L-P. Jelsness-Jørgensen1,2, A. Rekvin3, F. Lerang1

1Hospital Sykehuset Østfold, Department of Gastroenterology, Sarspborg, Norway, 2Østfold University College, Halden, Norway, 3Hospital Sykehuset Østfold, Department of Research, Sarspborg, Norway

P369: The comparative frequency of clostridial infection in patients with ulcerative colitis receiving mesenchymal stromal cells and anti-cytokine therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Knyazev1, A. Kagramanova*1, M. Chernova2, I. Korneeva1, D. Kulakov1, A. Parfenov1

1Moscow Clinical Scientific Center named after A. S. Loginov, Department of inflammatory bowel diseases, Moscow, Russian Federation, 2Moscow Clinical Scientific Center named after A. S. Loginov, Infection department, Moscow, Russian Federation

P370: Quality of life of patients with inflammatory bowel diseases in remission on different forms of treatment

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Kalaba*1, M. Markovic2, M. Jankovic1, D. Zaric1, S. Markovic1, P. Svorcan1

1Clinical Center Zvezdara, Department of Gastroenterology, Belgrade, Serbia, 2Institute of Public Health of Belgrade, Health Promotion, Belgrade, Serbia

P371: Outcome of immediate infliximab optimisation based on rapid assessment of serum drug and faecal calprotectin concentrations in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Farkas*1, K. Szántó1, D. Kata2, A. Bálint1, Á. Milassin1, A. Fábián1, R. Bor1, M. Rutka1, Z. Szepes1, I. Soós1, F. Nagy1, I. Földesi2, T. Molnár1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary

P372: Neurological symptoms and imaging abnormalities in brain MRI in patients with Crohn’s disease receiving anti-TNFa therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Papatheodoridi*1, A. Euthumiou2, N. Perlepe3, F. Gagas3, M. Gizis3, S. Lagou3, G. Kounadis3, J. Koutsounas3, G. Bamias3

1GI Unit, 3rd Academic Department of Internal Medicine, Athens, Greece, 2General Hospital ‘Laikon’, Neurological Unit,, Athens, Greece, 3Sotiria Hospital, National and Kapodistrian University of Athens, GI-Unit, 3rd Academic Department of Internal Medicine, Athens, Greece

P373: Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn’s disease: Phase 2 trial results

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Louis*1, W. J. Sandborn2, G. D’Haens3, F. Baert4, J. Kalabic5, K. Wallace6, W-J. Lee6, B. G. Feagan7

1University Hospital CHU of Liège, Liège, Belgium, 2University of California San Diego, La Jolla, USA, 3Academic Medical Center, Amsterdam, The Netherlands, 4AZ Delta Roeselare-Menen, Menen, Belgium, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6AbbVie Inc., North Chicago, USA, 7University of Western Ontario, Robarts Research Institute, London, Canada

P374: Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Vermeire1, Ž. Krznarić2, T. Kobayashi3, J. Chen4, C. Agboton5, K. Kisfalvi4, H. Patel*6, W. Sandborn7

1University Hospitals Leuven, Leuven, Belgium, 2University Hospital Centre Zagreb, Zagreb, Croatia, 3Kitasato University Kitasato Institute Hospital, Tokyo, Japan, 4Takeda Development Center Americas Inc., Cambridge, USA, 5Takeda Pharmaceuticals International AG, Zurich, Switzerland, 6Takeda Pharmaceuticals International, Deerfield, USA, 7University of California - San Diego, La Jolla, USA

P375: Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series

ECCO '19 Copenhagen

Year: 2019
Authors:

F. M. Phillips*1, B. Verstockt2,3, S. Sebastian4,5, D. G. Ribaldone6, S. Vavricka7, K. Konstantinos8, E. Slattery9, N. de Suray10,11, C. Flores12, W. Fries13, F. Vincenzi14, E. Capoferro15, O. Bachmann16, U. Kopylov17, ECCO CONFER Investigators1

1St Mark's Hospital, Inflammatory Bowel Disease, London, UK, 2University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 4Hull and East Yorkshire Hospitals NHS Trust, Inflammatory Bowel Disease Unit, Hull, UK, 5University of Hull and York, Hull York Medical School, Hull, UK, 6University of Turin, Surgical Sciences, Turin, Italy, 7University Hospital Zurich, Medicine, Zurich, Switzerland, 8University of Ioannina School of Medical Sciences, Gastroenterology, Ioannina, Greece, 9University Hospital Galway, Gastroenterology, Galway, Ireland, 10Grand Hopital de Charleroi, Gastroenterology and Hepatology, Charleroi, Belgium, 11University Hospital Saint-Luc, Gastroenterology and Hepatology, Bruxelles, Belgium, 12Hospital de Clinicas de Porto Alegre, Gastroenterology, Rio Grande do Sul, Brazil, 13University Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy, 14University of Parma, Gastroenterology and Endoscopy Unit, Parma, Italy, 15Sacro Cuore Don Calabria of Negrar, Negrar, Italy, 16Hannover Medical School, Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 17Sheba Medical Centre, Gastroenterology, Ramat Gan, Israel

P376: Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Danese1, S. Adsul*2, D. Lindner2, S. Jones3, H. Patel4, J-F. Colombel5

1Humanitas University, Milan, Italy, 2Takeda Pharmaceuticals International AG, Zurich, Switzerland, 3Takeda Development Centre Europe Ltd., London, UK, 4Takeda Pharmaceuticals International, Deerfield, USA, 5Icahn School of Medicine at Mount Sinai, New York, USA

P377: Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Risager Christensen*1, C. Steenholdt1, S. Buhl Næss-Schmidt1, J. Brynskov1, M. A. Ainsworth1,2

1Herlev and Gentofte Hospital, Gastroentrology, Copenhagen, Denmark, 2Odense University Hospital, Gastroentrology, Odense, Denmark

P378: Changes in Simplified Endoscopic Score for Crohn’s disease (SES-CD) during a 16-week induction treatment with upadacitinib: analysis of the randomised controlled CELEST study

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Feagan*1, W. Sandborn2, S. Schreiber3, B. Huang4, G. Alperovich4, A. Pangan4, A. Lacerda4, G. D’Haens5

1Western University, London, Ontario, Canada, 2University of California San Diego, La Jolla, CA, USA, 3University Hospital Schleswig-Holstein, Kiel, Germany, 4AbbVie Inc., North Chicago, IL, USA, 5Amsterdam University Medical Centers, Amsterdam, The Netherlands

P379: Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naïve patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Latremouille-Viau1, R. Burne1, S. Shi1, S. Adsul2, H. Patel*2

1Analysis Group, Montreal, Canada, 2Takeda Pharmaceutical Company, Ltd., Deerfield, IL, USA